Heron Therapeutics | HRTX - Operating Profit


Heron Therapeutics reported $38K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 29.13M 6.3M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Surmodics USD 58K 5.7M Jun/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026